Compare RGR & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGR | PEPG |
|---|---|---|
| Founded | 1949 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.9M | 425.1M |
| IPO Year | 1994 | 2022 |
| Metric | RGR | PEPG |
|---|---|---|
| Price | $38.93 | $5.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $43.00 | $11.67 |
| AVG Volume (30 Days) | 135.6K | ★ 578.7K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ 25.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $546,057,000.00 | N/A |
| Revenue This Year | $1.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.94 | N/A |
| 52 Week Low | $28.33 | $0.89 |
| 52 Week High | $48.21 | $7.80 |
| Indicator | RGR | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 40.90 |
| Support Level | $35.41 | $5.04 |
| Resistance Level | $47.86 | $5.50 |
| Average True Range (ATR) | 1.35 | 0.57 |
| MACD | 0.07 | -0.13 |
| Stochastic Oscillator | 72.24 | 12.17 |
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.